drugset / Trial / NCT00985166

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

NCT00985166

Phase 3 Completed 801 enrolled Merck Sharp & Dohme LLC
RandomizedParallel-groupDouble-blindPrevention

Summary

The study was conducted to determine if ProQuad may be used in place of the second dose of M-M-R II routinely given to children 4 to 6 years old who were previously immunized with M-M-R II and Varivax.

Timeline

Start
2000-08
Primary completion
2002-05
Completion
2003-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator M-M-R II Vaccine 0.5 ml Subcutaneous
Subject ProQuad Vaccine 0.5 ml Subcutaneous
Comparator Varivax Vaccine 0.5 ml Subcutaneous